Skip to main content
Premium Trial:

Request an Annual Quote

NGeneBio Partners With MDx Company Genolution to Launch Automated NGS System

NEW YORK – South Korean next-generation sequencing-based diagnostic firm NGeneBio announced Wednesday that it has signed a memorandum of understanding with molecular diagnostics company Genolution to develop and launch an automated NGS system. 

The companies plan to launch an expandable system to automate the entire NGS testing workflow, including nucleic acid extraction, library production, and data analysis steps, NGeneBio said in a statement. The firms will also jointly market their products using their overseas sales networks. The automated system is intended to prevent errors caused by manual work, reduce test time, and provide quick and accurate test results, NGeneBio added. 

Genolution said in a statement that the partnership is expected to accelerate Genolution's movement into the NGS precision diagnostics field. NGeneBio added that the collaboration will further strengthen the company's technical capabilities in the in vitro diagnostics space and secure global market competitiveness. 

Genolution, also based in South Korea, specializes in automated nucleic acid extraction equipment that can be applied to a variety of disease areas, including cervical cancer, influenza, sexually transmitted infections, and intestinal bacteria. NGeneBio offers multiple NGS-based solutions, including cancer diagnostic products.